Profiel
Robert H.
Tidwell worked as the Director-Worldwide Pharmaceutical Licensing at Eli Lilly & Co. from 1969 to 1985.
He then worked as the Vice President-Marketing & Business Development at Genetics Institute LLC from 1988 to 1993, and as the Chief Operating Officer at Alseres Pharmaceuticals, Inc. in 1993-1994.
Later, he worked as the Vice President-Business Development at Calydon, Inc. from 1998 to 2000, and as the Senior Vice President-Corporate Development at Cell Genesys, Inc. from 2000 to 2009.
He also worked as the Chief Business Officer at Ritter Pharmaceuticals, Inc. Additionally, he earned an undergraduate degree and an MBA from The Ohio State University.
Eerdere bekende functies van Robert H. Tidwell
| Bedrijven | Functie | Einde |
|---|---|---|
Cell Genesys, Inc.
 Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer. | Corporate Officer/Principal | 14-10-2009 |
Calydon, Inc.
 Calydon, Inc. Medical SpecialtiesHealth Technology Part of ANI Pharmaceuticals, Inc., Calydon, Inc. develops therapeutic products for cancer. The company is based in Sunnyvale, CA. Calydon was acquired by Cell Genesys, Inc. on September 05, 2001 for $17.68 million. | Corporate Officer/Principal | 01-01-2000 |
| ALSERES PHARMACEUTICALS, INC. | Operationeel Directeur | 01-01-1994 |
Genetics Institute LLC
 Genetics Institute LLC Pharmaceuticals: MajorHealth Technology Genetics Institute LLC develops pharmaceutical products through recombinant DNA and other genetic technologies. It develops drugs to make the blood of hemophiliacs clot, as well as substances that stimulate the production of red and white blood cells and proteins that enhance bone growth. The company was founded in 1980 and is headquartered in Cambridge, MA. | Verkoop & Marketing | 01-01-1993 |
| ELI LILLY AND COMPANY | Corporate Officer/Principal | 01-01-1985 |
Opleiding van Robert H. Tidwell
| The Ohio State University | Masters Business Admin |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| ALSERES PHARMACEUTICALS, INC. | Health Technology |
| ELI LILLY AND COMPANY | Health Technology |
| Bedrijven in privébezit | 4 |
|---|---|
Cell Genesys, Inc.
Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer. | Health Technology |
Calydon, Inc.
Calydon, Inc. Medical SpecialtiesHealth Technology Part of ANI Pharmaceuticals, Inc., Calydon, Inc. develops therapeutic products for cancer. The company is based in Sunnyvale, CA. Calydon was acquired by Cell Genesys, Inc. on September 05, 2001 for $17.68 million. | Health Technology |
Genetics Institute LLC
Genetics Institute LLC Pharmaceuticals: MajorHealth Technology Genetics Institute LLC develops pharmaceutical products through recombinant DNA and other genetic technologies. It develops drugs to make the blood of hemophiliacs clot, as well as substances that stimulate the production of red and white blood cells and proteins that enhance bone growth. The company was founded in 1980 and is headquartered in Cambridge, MA. | Health Technology |
Ritter Pharmaceuticals, Inc.
 Ritter Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Ritter Pharmaceuticals, Inc. engages in the development of novel therapeutic products which modulate the human gut microbiome to treat digestive disorders and gastrointestinal diseases. It focuses on the development and commercialization of RP-G28. The company was founded by Andrew J. Ritter and Ira E. Ritter on March 29, 2004 and is headquartered in Los Angeles, CA. | Health Technology |